MedinCell SA · EURONEXT:MEDCL
MedinCell SA — FY2020-2021 Earnings Presentation
8 slides from MedinCell SA's earnings presentation, June 2021
Slide 1: Results of the 2020-2021 financial year ended March 31, 2021
Videoconference Results of the 2020-2021 financial year ended on March 31, 2021
Slide 2: Development pipeline
mdc-GRT Tacrolimus Organ Transplant mdc-TTG Ivermectin Covid-19 mdc-WWM progestin molecule (non-MPA) Contraception mdc-ANG Confidential Antipsychotic mdc-STM Ivermectin Malaria mdc-TJK mdc-CWM mdc-IRM Confidential Celecoxib Risperidone mdc-KPT Antipsychotic Pain & inflammation Schizophrénia Confiden
Slide 3: Financial resources
Financial resources • 51 M€ cash and investments • 47,1 M€ in cash • 3,9 M€ in non-risky financial assets •
Slide 4: Financial resources: income and revenue
Financial resources • Income from ordinary activities: 11, 8 M€ (+96%) • Revenue: 8,2 M€ (+187%) • Research Tax Credit: 3,6 M€ (+14%) •
Slide 5: Financing
Financing • EIB: 5 M€ (3rd tranche) • State Guaranteed Loans (PGE): 13,7 M€ • Capital increases: 42 M€ (net) •
Slide 6: Expenses
Expenses • Expenses: 27,1 M€ (+8%) • R&D : 19,6 M€ • Marketing & BD : 1,8 M€ • General & administrative: 5,8 M€ •
Slide 7: Financial debt
Financial debt • Gross financial debt: 42,3 M€ • Net financial debt: (8,8) M€ •
Slide 8: Thank you
Tank you MedinCell 3, rue des frères Lumière 34830 Jacou • France www.medincell.com